We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+19.41%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$16.6B
AUM Growth
+$2.17B
Cap. Flow
-$81M
Cap. Flow %
-0.49%
Top 10 Hldgs %
31.47%
Holding
166
New
39
Increased
28
Reduced
33
Closed
30

Top Buys

Rank Stock Value
1
ARMK icon
Aramark
ARMK
+$366M
2
XLNX
Xilinx Inc
XLNX
+$332M
3
RTX icon
RTX Corp
RTX
+$299M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$289M
5
AVGO icon
Broadcom
AVGO
+$243M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$498M
2
INFO
IHS Markit Ltd. Common Shares
INFO
+$299M
3
ABBV icon
AbbVie
ABBV
+$298M
4
PANW icon
Palo Alto Networks
PANW
+$217M
5
BMY icon
Bristol-Myers Squibb
BMY
+$215M

Sector Composition

Rank Sector Weight
1 Healthcare 38.27%
2 Communication Services 13.23%
3 Financials 10.05%
4 Technology 9.85%
5 Industrials 8.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLVR
76
DELISTED
Clever Leaves Holdings Inc. Common Shares
CLVR
$28.7M 0.17%
+82,603
New +$26.8M
DMTK
77
DELISTED
DermTech, Inc. Common Stock
DMTK
$27.9M 0.17%
861,090
-358,909
-29% -$5.09M
BIIB icon
78
Biogen
BIIB
$30.7B
$25.2M 0.15%
+103,000
New +$26.6M
CNST
79
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$21.6M 0.13%
+750,000
New +$18.9M
BEKE icon
80
KE Holdings
BEKE
$18.8B
$21.1M 0.13%
343,000
+8,000
+2% +$532K
GRFS
81
Grifois
GRFS
$5.4B
$20.6M 0.12%
1,115,000
-2,013,750
-64% -$37.3M
ZEAL
82
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
$18.3M 0.11%
510,000
+5,000
+1% +$188K
ATTO
83
DELISTED
Atento S.A.
ATTO
$18.2M 0.11%
2,230,357
– –
PLRX icon
84
Pliant Therapeutics
PLRX
$65M
$17.4M 0.1%
764,262
– –
DCPH
85
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$17.1M 0.1%
300,000
-30,000
-9% -$1.78M
INBX
86
DELISTED
Inhibrx, Inc. Common Stock
INBX
$16.8M 0.1%
510,000
+115,000
+29% +$3.06M
RC
87
Ready Capital
RC
$308M
$16.8M 0.1%
1,350,226
– –
ADVM
88
DELISTED
Adverum Biotechnologies
ADVM
$16.3M 0.1%
150,000
– –
BMY icon
89
Bristol-Myers Squibb
BMY
$132B
$15.5M 0.09%
250,000
-3,500,000
-93% -$215M
BMY.RT
90
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$14.8M 0.09%
21,400,000
-22,673,000
-51% -$48.3M
PRAX icon
91
Praxis Precision Medicines
PRAX
$10.1B
$13.8M 0.08%
+16,667
New +$9.73M
XPO icon
92
XPO
XPO
$23.7B
$13.1M 0.08%
+318,053
New +$11.5M
NTLA icon
93
Intellia Therapeutics
NTLA
$1.67B
$12.2M 0.07%
+225,000
New +$8.17M
TINV.U
94
DELISTED
Tiga Acquisition Corp. Units, each consisting of one Class A ordinary share and one half of one warrant
TINV.U
$11.4M 0.07%
+1,080,000
New +$11.2M
TECX
95
Tectonic Therapeutic
TECX
$606M
$11.1M 0.07%
66,250
-21,250
-24% -$3.78M
RCKT icon
96
Rocket Pharmaceuticals
RCKT
$394M
$11M 0.07%
+200,000
New +$7.29M
QURE icon
97
uniQure
QURE
$3.22B
$10.8M 0.07%
300,000
-150,000
-33% -$6.33M
CAS.U
98
DELISTED
Cascade Acquisition Corp. Units, each consisting of one share of Class A Common Stock and one-half o
CAS.U
$10.3M 0.06%
+990,000
New +$10.1M
KNTE
99
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$9.95M 0.06%
+250,000
New +$10M
ALBO
100
DELISTED
Albireo Pharma Inc
ALBO
$9.38M 0.06%
250,000
+50,000
+25% +$1.82M
2 3
4
5 6

Similar funds

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farallon Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Farallon Capital Management held 166 positions worth $16.6B, up 15% from $14.5B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Farallon Capital Management's Q4 2020 filing shows 39 new, 28 increased, 33 reduced and 30 closed positions. Its largest new stake was Aramark: 15,268,169 shares worth $424M. The largest sale was Immunomedics Inc, an estimated $498M.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, down from 41% a quarter earlier, followed by Communication Services and Financials.

  • Farallon Capital Management's largest Q4 2020 buy was Aramark: 15,268,169 shares worth $424M.
  • Farallon Capital Management added most to Willis Towers Watson in Q4 2020, an estimated $188M increase.
  • Farallon Capital Management's biggest Q4 2020 reduction was AbbVie, cutting an estimated $298M.
  • Farallon Capital Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $498M.
  • Farallon Capital Management's ten largest holdings make up 31% of its $16.6B portfolio in Q4 2020.
  • Farallon Capital Management opened 39 new positions and closed 30 in Q4 2020.
  • Farallon Capital Management's portfolio value rose 15% quarter-over-quarter to $16.6B.

Based on Farallon Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.